FrancophonIA/ELRC3.0 huggingface dataset:
English: Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction assay (PCR) (> 30 IU/ml), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
Maltese: Pazjenti eliġibbli għal dawn l-istudji kellhom epatite kronika Ċ ikkonfermata mill-assaġġ pożittiv permezz talpolymerase chain reaction (PCR) (> 30 IU/ml) għal HCV-RNA, bijopsija tal-fwied konsistenti ma dijanjosi istoloġika ta' epatite kronika mingħajr l-ebda kawża oħra għall-epatite kronika u kwantitajiet anormali ta' ALT fis-serum.
English: Ribavirin BioPartners must be used in combination with interferon alfa-2b (3 million international units [MIU] three times a week).
Maltese: Ribavirin BioPartners għandu jittieħed flimkien ma' interferon alfa-2b (3 miljun unità internazzjonali
English: Take special care with Ribavirin BioPartners
Maltese: Doża ta' kuljum ta' Ribavirin BioPartners
English: The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/ml (Amplicor) who were treated for 24 weeks with a 6 month follow-up period.
Maltese: It-tul tat-terapija kien 48 ġimgħa b'perijodu ta' follow up ta' 6 xhur ħlief għal pazjenti infettati b'ġenotipi 2 jew 3 u viral load < 800,000 IU/ml (Amplicor) li kienu trattati għal 24 ġimgħa b'perijodu ta' follow up ta' 6 xhur.
English: If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with Ribavirin and peginterferon alfa-2b or interferon alfa-2b be discontinued, and the patient followed, with psychiatric intervention as
Maltese: Jekk sintomi psikjatriċi jippersistu jew imorru għall-agħar, jew jiġu identifikati ħsibijiet suwiċidali, huwa rakkomandat li t-trattament b'Ribavirin u peginterferon alfa-2b jew interferon alfa-2b jitwaqqaf, u lpazjent jibqa' taħt osservazzjoni, b'interventi għal għajnuna psikjatrika xierqa.
English: - Severe hepatic impairment (Child-Pugh Classification B or C) or decompensated cirrhosis of
Maltese: − Indeboliment sever tal-fwied (Klassifikazzjoni ta' Child Pugh B jew Ċ) jew ċirrosi mhux
English: Depression, anxiety, emotional lability, insomnia Suicidal ideation, psychosis, aggressive behaviour, confusion, agitation, anger, mood altered, abnormal behaviour, nervousness, sleep disorder, decreased libido apathy,
Maltese: Ħsibijiet suwiċidali, psikosi, mġieba aggressiva, konfużjoni, aġitazzjoni, rabja, tibdil fil-burdata, imġiba anormali, nervożità, disturbi fl-irqad, tnaqqis ta' xewqa sesswali, apatija, ħolm anormali, biki Tenattivi ta' suwiċidju, attakk ta' paniku, alluċinazzjoniet
English: Laboratory tests: Standard haematologic tests and blood chemistries (complete blood count [CBC] and differential, platelet count, electrolytes, serum creatinine, liver function tests, uric acid) must be conducted in all patients prior to initiating therapy.
Maltese: Qabel ma tinbeda t-terapija fil-pazjenti kollha għandhom isiru t-testijiet ematoloġiċi standard u kimiċi tad-demm (għadd sħiħ u divrenzjali ta' ċelluli tad-demm [CBC], l-għadd ta' plejtlits, elettroliti, kreatinin fis-serum, testijiet tal-funzjoni tal-fwied u tal-aċidu uriku).
English: Renal and urinary disorders Common:
Maltese: Funzjoni renali:
English: HCV-RNA should be measured periodically during treatment (see section 4.2).
Maltese: L-HCV-RNA għandhom jitkejlu perjodikament waqt il-kura (ara sezzjoni 4.2).
English: Children 3 years of age and older and adolescents: Ribavirin BioPartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children 3 years of age and older and adolescents, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.
Maltese: Ribavirin BioPartners huwa intenzjonat biex jintuża, fi programm ta' terapija kkombinat ma' interferon alfa2b, għal trattament fi tfal minn 3 snin 'il fuq u adolexxenti, li għandhom it-tipi kollha ta' epatite Ċ kronika ħlief ġenotip 1, li ma kienux ikkurati qabel, mingħajr fwied mhux kompensat, u li huma pożittivi għal HCV-RNA.
English: Micturition frequency, polyuria, urine abnormality
Maltese: Frekwenza biex tgħaddi l-awrina, poliurja, awrina anormali
English: If you are a HCV/HIV co-infected adult patient receiving anti-HIV treatment, the addition of Ribavirin BioPartners and peginterferon alfa-2b may increase your risk of worsening liver function highly active anti-retroviral therapy (HAART) and increase your risk of lactic acidosis, liver failure, and blood abnormalities development (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets) (NRTI).
Maltese: Jekk int pazjent adult li qed tbati b'HCV/HIV u qed tirċievi kura kontra l-HIV, iż-żieda ta' Ribavirin BioPartners u peginterferon alfa-2b tista' żżid ir-riskju tiegħek li l-funzjoni tal-fwied tmur għall-agħar terapija kontra r-retrovajrus attiva ħafna (HAART) u iżżid ir-riskju ta' aċidosi lattika, insuffiċjenza epatika u jiżviluppaw abnormalitajiet tad-demm (tnaqqis fin-numru ta' ċelluli ħomor tad-demm li jġorru l-ossiġnu, ċerti ċelluli bojod tad-demm li jiġġieldu l-infezzjoni, u ċelluli li jgħaqqdu d-demm imsejħa plejtlits) (NRTI).
English: Anorexia, increased appetite, decreased appetite Hypertriglyceridemia, hyperuricemia
Maltese: Anoreksja, żieda fl-aptit, tnaqqis fl-aptit
English: - Initiation of peginterferon alfa-2b is contraindicated in HCV/HIV patients with cirrhosis and a
Maltese: Pazjenti infettati fl-istess ħin b'HCV/HIV
English: Patients were randomized to receive either ribavirin (800-1,200 mg/day based on weight) plus peginterferon alfa-2b (100 or 150 μg/week based on weight) or ribavirin (800-1,200 mg/day based on weight) plus interferon alfa-2b (3 MIU TIW).
Maltese: Il-pazjenti ntgħażlu b'mod każwali biex jew jirċievu ribavirin (800-1,200 mg/jum skont il-piż) flimkien ma' peginterferon alfa-2b (100 jew 150 µg/ġimgħa skont il-piż) jew ribavirin (800-1,200 mg/jum skont il-piż) flimkien ma' interferon alfa-2b (3 MIU TIW).
English: Liver biopsies were obtained before and after treatment in Study 1 and were available for 210 of the 412 subjects (51 %).
Maltese: Bijopsiji tal-fwied ittieħdu qabel u wara t-trattament fi Studju 1 u kienu disponibbli għal 210 mill-412-il individwu (51 %).
English: Prior to initiation of interferon alfa-2b therapy, TSH levels must be evaluated and any thyroid abnormality detected at that time must be treated with conventional therapy.
Maltese: Qabel ma tinbeda terapija b'interferon alfa-2b, il-livelli ta' TSH għandhom jiġu valorizzati u kull abormalità li tinstab f'dak il-ħin għandha tiġi trattata b'terapija konvenzjonali.
English: In a juvenile rat toxicity study, pups dosed from postnatal day 7 to 63 with 10, 25 and 50 mg/kg of ribavirin demonstrated a dose-related decrease in overall growth, which was subsequently manifested as slight decreases in body weight, crown-rump length and bone length.
Maltese: Fi studju war it-tossiċità fuq firien, frieħ li ngħataw doża ta' bejn 7 sa 63 jum wara t-twelid b'10, 25 u 50 mg/kg ta' ribavirin urew tnaqqis ġenerali fit-tkabbir skont id-doża, li wara deher bħala tnaqqis żgħir fil-piż tal-ġisem, it-tul tal-crown-rump (bejn ir-ras u l-patata) u t-tul tal-għadam.
English: Patients were randomized to receive either ribavirin (800 mg/day) plus peginterferon alfa-2b (1.5 μg/kg/week) or ribavirin (800 mg/day) plus interferon alfa-2b (3 MIU TIW) for 48 weeks with a follow-up period of 6 months.
Maltese: Il-pazjenti ngħataw b'mod każwali jew ribavirin (800 mg/jum) flimkien ma' peginterferon alfa-2b (1.5 µg/kg/ġimgħa) jew ribavirin (800 mg/jum) flimkien ma' interferon alfa-2b (3 MIU TIW) għal 48 ġimgħa b'perijodu ta' follow-up għal 6 xhur.
English: Arthritis, back pain, muscle spasms, pain in extremity
Maltese: Artrite, uġigħ fid-dahar, spażmi fil-muskoli, uġigħ flestremità
English: No interaction studies have been conducted with ribavirin and other medicinal products, except for peginterferon alfa-2b, interferon alfa-2b and antacids.
Maltese: Ma saru l-ebda studji dwar l-interazzjoni bejn ribavirin u prodotti mediċinali oħra, ħlief għal peginterferon alfa-2b, interferon alfa-2b u antaċidi.
English: HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and HAART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Maltese: Pazjenti li jkollhom HCV/HIV fl-istess ħin li jkunu qed jirċievu trattament b'peginterferon alfa-2b/ribavirin u HAART jistgħu jkunu f'riskju akbar li jiżviluppaw anormalitajiet ematoloġiċi (bħala neutropenja, tromboċitopenja u anemija) meta mqabbla ma' pazjenti infettati b'HCV biss.
English: For children and adolescents weighing less than 47 kg a solution formulation is available.
Maltese: Għal tfal u adolexxenti li jiżnu anqas minn 47 kg, teżisti formulazzjoni bħala soluzzjoni.
English: In 3- and 6-month studies in mice to investigate Ribavirin-induced testicular and sperm effects, abnormalities in sperm, occurred at doses of 15 mg/kg and above.
Maltese: Fi studji ta' 3 u 6 xhur fuq il-ġrieden sabiex jiġu mistħarrġa l-effetti fuq it-testikuli u fuq l-isperma kkaġunati minn Ribavirin, anormalitajiet fl-isperma seħħew f'dożi ta' 15 mg/kg u aktar.
English: - Fertility: In animal studies, ribavirin produced reversible effects on spermatogenesis (see section 5.3).
Maltese: Fi studji fuq l-annimali, ribavirin ikkaġuna effetti riversibbli fuq l-ispermatoġenesi (ara sezzjoni 5.3).
English: Female: amenorrhea, menorrhagia, menstrual disorder, dysmenorrhea, breast pain, ovarian disorder, vaginal disorder.
Maltese: Disturbi fis-sistema riproduttiva u tas-sider Nisa: amenorrea, menorragja, disturbi menstruwali, dismenorrea, uġigħ fis-sider, disturb ovarjan, disturb
English: Diarrhoea, vomiting, nausea, abdominal pain Ulcerative stomatitis, stomatitis, mouth ulceration, colitis, upper right quadrant pain, dyspepsia, gastroesophoageal reflux*, glossitis, cheilitis, abdominal distension, gingival bleeding, gingivitis, loose stools, tooth disorder, constipation,
Maltese: Dijarea, remettar, tqalligħ, uġigħ addominali Stomatite ulċerattiva, stomatite, ulċera fil-ħalq, kolite, uġigħ fil-kwadrant lemini ta' fuq, dispepsja, ittella' millistonku*, glossite, kejlite, nefħa addominali, ħanek bid-demm, ġinġivite, ippurgar maħlul, disturbi fis-snien,
English: Multiple-dose pharmacokinetic properties for ribavirin and interferon alfa-2b in children and adolescents with chronic hepatitis C between 5 and 16 years of age are summarized in Table 9.
Maltese: Il-karatteristiċi tal-farmakokinetiċi b'ħafna dożi għal pilloli ribavirin u interferon alfa-2b fi tfal u adoloxxenti b'epatite Ċ kronika ta' età bejn 5 u 16-il sena qed jintwerew fil-qosor f'Tabella 9.
English: Ear and labyrinth disorders Common:
Maltese: Disturbi dentali u periodontali:
English: The combination of Ribavirin BioPartners with interferon alfa-2b is used to treat patients 3 years of age and older who have chronic hepatitis C (HCV) infection, except genotype 1.
Maltese: Il-kombinazzjoni ta' Ribavirin BioPartners ma' interferon alfa-2b tintuża biex jiġu kkurati pazjenti ta' 18-il sena jew aktar li għandhom infezzjoni b'epatite C kronika (HCV).
English: Study 1 (see section 5.1), decrease in absolute neutrophil count levels below 500 cells/mm3 was observed in 4 % (8/194) of patients and decrease in platelets below 50,000/mm3 was observed in 4 %
Maltese: Fi Studju 1 (ara sezzjoni 5.1), tnaqqis fl-għadd assolut tan-newtrofili taħt il-500 ċellula/mm3 deher f'4 % (8/194) tal-pazjenti u tnaqqis fl-għadd tal-plejtlets għal taħt 50,000/mm3 deher f'4 % (8/194) tal-pazjenti li kienu jiċievu ribavirin f'kombinazzjoni ma' peginterferon alfa-2b.
English: In a clinical trial with 107 children and adolescent patients (3 to 17 years of age) treated with combination therapy of peginterferon alfa-2b and ribavirin, dose modifications were required in 25 % of patients, most commonly for anaemia, neutropenia and weight loss.
Maltese: Fi prova klinika b'107 pazjent tifel u tifla u adolexxenti (3 sa 17-il sena) ikkurati b'terapija kombinata ta' peginterferon alfa-2b u ribavirin, bidliet fid-doża kienu meħtieġa f'25 % tal-pazjenti, l-aktar komuni minħabba anemija, newtropenija jew telf tal-piż.
English: Reported adverse reactions listed in Table 5 are based on experience from the two multicentre children and adolescents clinical trials using ribavirin with interferon alfa-2b or peginterferon alfa-2b.
Maltese: Reazzjonijiet avversi rrappurtati elenkati f'Tabella 5 huma bbażati fuq esperjenza miż-żewġ provi kliniċi multiċentriċi fuq tfal u adolexxenti b'ribavirin flimkien ma' interferon alfa-2b jew peginterferon alfa-2b.
English: Ribavirin BioPartners is not recommended for use in patients under the age of 3 years.
Maltese: Ribavirin BioPartners mhux irrakkomandat għall-użu f'pazjenti taħt 3 snin.
English: You must have a negative pregnancy test before treatment, each month during treatment, and for the 4 months after treatment is stopped.
Maltese: Irid ikollok test tat-tqala li jkun negattiv qabel it-trattament, kull xahar waqt it-trattament, u għall-4 xhur wara li t-trattament jitwaqqaf.
English: Retinopathy including retinal haemorrhages, retinal exudates, papilloedema, optic neuropathy and retinal artery or vein occlusion which may result in loss of vision have been reported in rare instances with combination therapy with alpha interferons.
Maltese: Retinopatija, li tinkludi emorraġiji retinali, tnixxijiet tar-retina, papilloedema, newropatija ottika u sadda tal-arterja jew vina tar-retina li tista' twassal għal telf tal-vista kienu rappurtati f'xi każijiet ta' terapija kkombinata ma' alfa interferons.
English: Limited safety data (N = 25) are available in co-infected patients with CD4+ cell counts < 200/µl (see section 4.4).
Maltese: Hemm tagħrif limitat (N = 25) dwar is-sigurtà f'pazjenti li jkollhom infezzjoni fl-istess ħin b'għadd ta' ċelluli CD4+ < 200/µl (ara
English: The use of ribavirin is contraindicated in patients with severe hepatic impairment or decompensated cirrhosis (see section 4.3).
Maltese: L-użu ta' ribavirin hu kontraindikat f'pazjenti b'indeboliment serju tal-fwied jew cirrożi dikumpensata (ara sezzjoni 4.3).
English: Patients whose dose of Ribavirin BioPartners is reduced to 600 mg daily receive one 200 mg tablet in the morning and two 200 mg tablets in the evening.
Maltese: Pazjenti li jkollhom id-doża ta' Ribavirin BioPartners imnaqqsa għal 600 mg kuljum jirċievu pillola waħda ta' 200 mg filgħodu u żewġ pilloli ta' 200 mg
English: Study 22
Maltese: Tabella 5
English: - eye problems including damage to the retina, obstruction of the retinal artery, inflammation of the optic nerve, swelling of the eye and cotton wool spots (white deposits on the retina), - enlarged abdominal area, heartburn, trouble having bowel movement or painful bowel movement, - acute hypersensitivity reactions including urticaria (hives), bruises, intense pain in a limb, leg or thigh pain, loss of range of motion, stiffness, sarcoidosis (a disease characterised by persistent fever, weight loss, joint pain and swelling, skin lesions and swollen glands).
Maltese: - problemi fl-għajnejn inkluż ħsara fir-retina, sadda ta' l-arterja tar-retina, infjammazzjoni tannerve ottiku, nefħa ta' l-għajn u tikkek qieshom tajjar (jiffurmaw dbabar bojod fuq ir-retina), - erja addominali tintefaħ, ħruq ta' stonku, tbatija fl-ippurgar jew uġigħ waqt l-ipurgar, - reazzjonijiet ta' sensittività eċċessiva akuta inklużi urtikarja (ħorriqija), tbenġil, uġigħ qawwi f'xi drigħ jew riġel, uġigħ f'sieq jew koxxa, telf tal-medda tal-moviment, ebusija, sarkojdożi (marda karatterizzata b'deni persistenti, telf fil-piż, uġigħ fil-ġogi u nefħa, ġrieħi fil-ġilda u
English: Interferon alfa-2b (pegylated and non-pegylated) therapy may be initiated if TSH levels can be maintained in the normal range by medication.
Maltese: It-terapija b'interferon alfa-2b (pegilat u mhux pegilat) tista' tinbeda jekk il-livelli ta' TSH ikunu jistgħu jinżammu fil-medda normali permezz tal-mediċini.
English: Cardiac disorders Common:
Maltese: Disturbi fis-sistema endokrina Komuni ħafna:
English: Most of the changes in laboratory values in the ribavirin/peginterferon alfa-2b clinical trial were mild or moderate.
Maltese: Ħafna mil-bidliet fir-riżultati tal-laboratorju fil-prova klinika b'ribavirin/peginterferon alfa-2b kienu ħfief jew moderati.
English: - itchy anal area (pinworms or ascarids), blistering rash (shingles), decreased sensitivity to touch, muscle twitching, pain in skin, paleness, peeling of skin, redness, swelling.
Maltese: - ħakk fiż-żona ta' l-anu (ħniex jew askaridi), raxx bi bżieżaq (ħruq ta' Sant' Antnin), tnaqqis sensittività biex tħoss, ġbid muskolari, uġigħ fil-ġilda, ġilda pallida ġilda titqaxxar, ħmura,
English: The mechanism by which ribavirin in combination with interferon alfa-2b exerts its effects against HCV is unknown.
Maltese: Il-mekkaniżmu li bih ribavirin flimkien ma' interferon alfa-2b jeżerċita l-effetti tiegħu kontra HCV mhux magħruf.
English: Table 2 Ribavirin BioPartners dose based on body weight when used in combination with interferon alfa-2b in children and adolescents Patient weight (kg)
Maltese: Tabella 2 Doża ta' Ribavirin BioPartners bażata fuq il-piż tal-ġisem meta jintuża f'kombinazzjoni ma' interferon alfa-2b fi tfal u adolexxenti Piż tal-ġisem (kg)
English: SVR after treatment of chronic HCV with non-pegylated interferon alfa-2b with ribavirin results in long-term clearance of the virus providing resolution of the hepatic infection and clinical 'cure' from chronic HCV.
Maltese: SVR wara kura b'HCV kroniku b'interferon alfa-2b (pegilat u mhux pegilat, bi jew mingħajr ribavirin) wassal għal tneħħija fuq terminu ta' żmien twil tal-virus b'hekk tgħaddi l-infezzjoni epatika ‘b'kura' klinika minn HCV kronika.
English: - Patients with chronic renal failure, patients with creatinine clearance < 50 ml/minute and/or on haemodialysis.
Maltese: − Pazjenti b'insuffiċjenza kronika renali, pazjenti bi tneħħija tal-kreatinina ta' < 50 ml/minuta
English: Myocardial infarction
Maltese: Disturbi psikjareiċi
English: Haematological abnormalities were more frequently reported in patients receiving ribavirin in combination with peginterferon alfa-2b when compared to patients receiving ribavirin in combination with interferon alfa-2b.
Maltese: Anormalitajiet ematoloġiċi kienu rappurtati b'mod aktar frekwenti f'pazjenti li kienu qed jirċievu ribavirin f'kombinazzjoni ma' peginterferon alfa-2b meta mqabbla ma' pazjenti li kienu qed jirċievu ribavirin f'kombinazzjoni ma' interferon alfa-2b.
English: Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin in combination with peginterferon alfa-2b.
Maltese: Jekk jogħġbok irreferi għas-Sommarju tal-Karatteristiċi tal-Prodott tal-prodotti mediċinali antiretrovirali li jkollhom jittieħdu fl-istess ħin ma' terapija HCV għal għarfien u ġestjoni tat-tossiċitajiet speċifiċi għal kull prodott u l-potenzjal ta' tossiċitajiet f'daqqa b'ribavirin f'kombinazzjoni ma' peginterferon alfa-2b.
English: - decreases in the number of red blood cells (that may cause fatigue, shortness of breath, dizziness), decrease in neutrophils (that make you more susceptible to different infections), - decrease in thyroid gland activity (which may make you feel tired, depressed, increase your sensitivity to cold and other symptoms), - feeling depressed or irritable, feeling sick to stomach, feeling unwell, mood swings, tired feeling, trouble falling asleep or staying asleep, virus infection, weakness, - diarrhoea, dizziness, fever, flu-like symptoms, headache, loss of or increase in appetite, loss of weight, decrease in the rate of growth (height and weight), pain on right side of ribs, pharyngitis (sore throat), shaking chills, stomach pain, vomiting, - dry skin, hair loss, irritation, pain or redness at the site of injection, itching, muscle pain, muscle aches, pain in joints and muscles, rash.
Maltese: Effetti sekondarji li kienu rrappurtati b'mod komuni ħafna: tnaqqis fin-numru ta' ċelluli ħomor tad-demm (li jista' jikkawża għeja, qtugħ ta' nifs, sturdament), tnaqqis fin-newtrofili (li jgħamluha aktar faċli li jaqbduk infezzjonijiet differenti), tnaqqis fl-attività tal-glandola tat-tirojde (li tista' ġġiegħlek tħossok għajjien, dipress, iżżid is-sensittività tiegħek għal ksieħ u sintomi oħrajn), - tħossok dipress jew irritabbli, tħoss l-istonku mhux floku, ma tħossokx tajjeb, tibdil fil-burdati, tħossok għajjien/a, problemi biex torqod jew biex tibqa' rieqed, infezzjoni virali, dgħjufija, dijarea, sturdament, temperatura għolja, sintomi bħal ta' l-influwenza, uġigħ ta' ras, nuqqas jew żieda fl-aptit, telf fil-piż, tnaqqis fir-rata tat-tkabbir (tul u piż), uġigħ fin-naħa tal-lemin talkustilji, farinġite (grieżem misluħin), dehxiet bi tregħid, uġigħ fl-istonku, rimettar, - ġilda xotta, jeħfief ix-xagħar, irritazzjoni, uġigħ jew ħmura fis-sit ta' l-injezzjoni, ħakk, uġigħ fil-muskoli, weġgħat fil-muskoli, uġigħ fil-ġogi u fil-muskoli, raxx.
English: Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorder, mania, confusion and alterations of mental status have been observed with alpha interferons.
Maltese: Effetti oħra marbuta mas-SNĊ kienu jinkludu mġieba aggressiva (xi drabi kontra individwi oħra, bħal ħsiebijiet ta' omiċidju), disturbi bipolari, manija, konfużjoni u bidliet fl-istat mentali dehru b'alfa interferons.
English: Mouth ulceration, stomatitis ulcerative, stomatitis, aphthous stomatitis, dyspepsia, cheilosis, glossitis, gastroesophoageal reflux, rectal disorder, gastrointestinal disorder, constipation, loose stools, toothache, tooth disorder, stomach discomfort,
Maltese: Ulċeri fil-ħalq, stomatite ulcerativa, stomatite, stomatite b'afti, dispepsja, keljożi, glossite, ittella' mill-istonku, disturbi fir-rektum, disturbi gastrointestinali, stitikezza, ippurhar merħi, uġigħ fis-snien, disturbi fis-snien, skumdità fl-istonku, uġigħ fil-ħalq
English: The use of Ribavirin and interferon alfa-2b or peginterferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated
Maltese: Waqt kura ta' sena b' ribavirin ikkombinat ma' interferon alfa-2b, xi tfal u adolexxenti ma kibrux jew ma żiedux fil-piż daqs kemm ikun mistenni.
English: Nervous system disorders Very common:
Maltese: Effetti sekondarji rrappurtati rari ħafna:
English: In the HIV-positive population receiving an NRTI regimen, physicians should carefully monitor markers of mitochondrial toxicity and lactic acidosis when ribavirin is
Maltese: Fil-popolazzjoni pożittiva għal HIV li qed jirċievu programm ta' trattament ta' NRTI, it-tobba għandhom josservaw b'attenzjoni l-markers ta' tossiċità mitokondrijali u aċidosi lattika meta jingħata ribavirin.
English: Visual disturbance, blurred vision, conjunctivitis, eye irritation, eye pain, abnormal vision, lacrimal gland disorder, dry eye
Maltese: Disturbi tal-vista, vista imċajpra, konġuntivite, irritazzjoni fl-għajn, uġigħ fl-għajnejn, vista abnormali, disturb ital-glandola lakrimali, għajn xotta
English: Headache, dizziness, dry mouth, concentration impaired Amnesia, memory impairment, syncope, migraine, ataxia, paraesthaesia, dysphonia, taste loss, hypoaesthesia, hyperaesthesia, hypertonia, somnolence, disturbance in attention, tremor, dysgeusia
Maltese: Amnesija, tfixkil fil-memorja, sinkope, emigranja, ataksja, paraesteżija, disfonja, telf fit-togħma, ipoestesija, iperestesija, ipertonja, ngħas, disturbi fl-attenzjoni, tregħid, disgewsja
English: - Hypersensitivity to the active substance or to any of the excipients.
Maltese: − Sensittività eċċessiva għas-sustanza attiva jew għal xi sustanzi mhux attivi.